查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2086171

神經調控市場：2026-2032年全球市場預測（依產品類型、技術、病患年齡層、應用和最終用戶分類）

Neuromodulation Market by Product Type, Technology, Patient Age Group, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，神經調控市場將成長至 106.5 億美元，複合年成長率為 7.04%。

主要市場統計數據
基準年 2025 66.1億美元
預計年份：2026年 70.6億美元
預測年份 2032 106.5億美元
複合年成長率 (%) 7.04%

神經調控執行摘要

神經調控正從植入式醫療設備的小眾領域發展成為精準神經科學、慢性疼痛治療​​、運動障礙管理、癲癇治療、精神疾病治療和骨盆底健康等領域的重要支柱。該領域得到了脊髓刺激、深部腦部刺激、迷走神經刺激、薦椎神經刺激和經顱磁刺激等臨床成熟療法以及新興的周邊神經刺激平台的支持。

神經調控領域的變革性變化

神經調控領域正因微型植入、可充電和免充電電源系統、核磁共振相容設備、定向導線、遠端編程以及微創輸送技術的進步而煥然一新。這些進步改善了患者選擇、治療永續性、刺激精度和術後管理，同時減輕了臨床醫生和護理團隊的負擔。

人工智慧對神經調控的累積影響

人工智慧 (AI) 正對整個神經調控過程產生累積影響，涵蓋患者識別、影像分析、訊號解讀、治療最佳化和遠端追蹤等各個環節。 AI 驅動的分析使臨床醫生能夠檢測電生理數據、穿戴式設備數據、圖像數據和患者報告結局 (PRO) 中的反應模式，從而實現更個性化的刺激參數設置，並在治療反應發生變化時早期療育。

主要區域洞察：亞太地區、北美地區、拉丁美洲地區、歐洲地區、中東和非洲地區

北美仍然是神經調控領域最成熟的地區，這得益於其高密度的專家群體、FDA已通過核准的醫療器材、完善的保險報銷機制、NIH資助的神經科學研究，以及龐大的慢性疼痛、癲癇和運動障礙患者群體。歐洲仍然是領先的臨床和監管中心，德國、法國、義大利、西班牙和英國為神經病學、神經外科、復健和疼痛管理提供了強大的基礎設施，同時也積極適應歐盟醫療設備法規更嚴格的要求和醫療技術評估標準。

各集團對關鍵區域的看法：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

東協市場正透過醫療旅遊、私人醫院網路以及新加坡、泰國和馬來西亞的專科醫療中心而日益重要，但保險報銷差異和勞動力短缺仍然導致低收入成員國獲得醫療保健的機會不均等。在海灣合作理事會（GCC）國家，由於政府主導的醫療現代化、高階醫院引進醫療設備以及對疼痛、運動障礙、癲癇和復健服務的需求不斷成長，神經調控技術的應用正在取得進展。

對主要神經調控市場關鍵國家的洞察

美國憑藉其FDA核准流程、大規模的醫院系統、醫療保險福利趨勢、活躍的臨床試驗以及慢性疼痛的高發生率，已成為神經調控領域的全球商業性中心。加拿大採用更集中化的進入模式，該模式由省級報銷系統、醫療技術評估和專科轉診途徑構成。墨西哥和巴西擁有拉丁美洲最大的商業機遇，這得益於其龐大的患者群體、不斷擴大的替代醫學服務覆蓋範圍以及日益提升的神經系統疾病和疼痛管理能力。

為神經調控產業的領導者提供的實用建議

產業領導者應優先收集證據，證明神經調控與功能改善、藥物劑量減少、生活品質提高、症狀持續控制以及整體醫療成本降低之間存在關聯。市場進入團隊應利用來自隨機試驗、註冊研究、真實世界結果、患者報告結果以及針對慢性疼痛、帕金森氏症、憂鬱症、憂鬱症、膀胱過動症和骨盆底功能障礙的亞組分析的證據，為保險公司準備相關資料。

調查方法

本執行摘要基於系統的二手研究方法，利用公開可獲取和可驗證的來源，包括調查方法、臨床指南、同行檢驗資訊來源、政府衛生統計數據、醫院採購趨勢、報銷框架以及世界衛生組織、美國疾病管制與預防中心、美國食品藥物管理局、美國國立衛生研究院和歐洲監管機構等認可的公共衛生機構。

結論

神經調控正步入一個新的發展階段，其特點是精準刺激、人工智慧驅動的個人化治療、遠距醫療以及對治療結果的更嚴格課責。在慢性疼痛、運動障礙、癲癇、精神疾病、骨盆底功能障礙和自主神經系統疾病等領域持續存在的臨床需求推動下，神經調控已成為神經技術領域最具戰略意義的細分市場之一。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 神經調控市場：依產品類型分類

  • 深部腦部刺激
    • 定向
    • 戒指
  • 薦椎神經刺激
    • 不可充電
    • 可充電的
  • 脊髓刺激療法
    • 閉合迴路
    • 開放回路
  • 經皮電神經刺激
    • 可攜式的
    • 固定式
  • 迷走神經刺激
    • 嵌入式
    • 非侵入性

第8章：神經調控市場：依技術分類

  • 侵入性
  • 非侵入性

第9章 神經調控市場：依病患年齡層別分類

  • 兒童
  • 成人
  • 老年人

第10章：神經調控市場：依應用領域分類

  • 慢性疼痛管理
  • 憂鬱症
  • 癲癇
  • 運動障礙
  • 尿失禁

第11章 神經調控市場：依最終用戶分類

  • 門診手術中心
  • 居家照護
  • 醫院

第12章 神經調控市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 神經調控市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 神經調控市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • BioControl by Merck
  • BioElectronics Corporation
  • Boston Scientific Corporation
  • EndoStim, Inc.
  • Impulse Dynamics
  • Livanova
  • Mainstay Medical
  • Medtronic PLC
  • MicroTransponde
  • NeuroMetrix
  • Neuronetics, Inc.
  • NeuroPace, Inc.
  • NeuroSigma, Inc.
  • Nevro Corp.
  • Saluda Medical
  • SceneRay Corporation, Limited
  • Soterix Medical
  • Synapse Biomedical
Product Code: MRR-036C5CF3B4DB

The Neuromodulation Market is projected to grow by USD 10.65 billion at a CAGR of 7.04% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.61 billion
Estimated Year [2026] USD 7.06 billion
Forecast Year [2032] USD 10.65 billion
CAGR (%) 7.04%

Neuromodulation Executive Summary

Neuromodulation is moving from a niche implantable-device category to a core pillar of precision neuroscience, chronic pain care, movement disorder management, epilepsy treatment, psychiatric care, and pelvic health. The field is anchored by clinically established modalities such as spinal cord stimulation, deep brain stimulation, vagus nerve stimulation, sacral nerve stimulation, transcranial magnetic stimulation, and emerging peripheral nerve stimulation platforms.

Demand is supported by measurable disease burden: the WHO identifies neurological conditions as a leading global cause of illness and disability, Parkinson's disease affected more than 8.5 million people in 2019, epilepsy affects about 50 million people worldwide, and the CDC reported chronic pain in roughly one in five U.S. adults. These realities make neuromodulation a strategically important field for payers, hospitals, device manufacturers, clinicians, and digital health innovators seeking durable, patient-specific alternatives to medication-only care.

Transformative Shifts in the Neuromodulation Landscape

The neuromodulation landscape is being reshaped by miniaturized implants, rechargeable and recharge-free power systems, MRI-conditional devices, directional leads, remote programming, and less invasive delivery approaches. These advances are improving patient selection, therapy durability, stimulation precision, and post-implant management while reducing friction for clinicians and care teams.

At the same time, value-based healthcare is changing purchasing behavior. Hospitals and payers increasingly expect real-world evidence, patient-reported outcomes, fewer revision procedures, and clear cost offsets from reduced medication dependence, fewer hospital visits, and improved functional status. Regulatory scrutiny is also raising the importance of post-market surveillance, cybersecurity, usability, and long-term device reliability across implantable and noninvasive neuromodulation systems.

Cumulative Impact of Artificial Intelligence in Neuromodulation

Artificial intelligence is creating cumulative impact across the neuromodulation pathway, from patient identification and imaging analytics to signal interpretation, therapy optimization, and remote follow-up. AI-enabled analytics can help clinicians detect response patterns in electrophysiology, wearable data, imaging, and patient-reported outcomes, supporting more personalized stimulation parameters and earlier intervention when therapy response changes.

The most important long-term opportunity is closed-loop neuromodulation, where devices sense neural or physiologic signals and adjust stimulation in response. FDA-authorized sensing-capable deep brain stimulation systems and remote monitoring tools demonstrate the direction of travel, although algorithm validation, cybersecurity, data governance, bias mitigation, interoperability, and clinical accountability remain essential adoption requirements.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

North America remains the most mature neuromodulation region due to high specialist density, FDA-cleared device availability, established reimbursement pathways, NIH-supported neuroscience research, and large chronic pain, epilepsy, and movement disorder populations. Europe continues to be a major clinical and regulatory hub, with Germany, France, Italy, Spain, and the United Kingdom contributing strong neurology, neurosurgery, rehabilitation, and pain-management infrastructure while adapting to stricter EU Medical Device Regulation requirements and health technology assessment expectations.

Asia-Pacific is the fastest-evolving opportunity as Japan, China, South Korea, Australia, and India expand access to advanced neurological care, imaging capacity, and hospital-based device programs. Latin America is led by Brazil and Mexico, where private healthcare expansion and specialist centers support adoption, although reimbursement and affordability constraints remain material barriers. The Middle East, especially GCC health systems, is investing in specialty hospitals, advanced procedures, and medical technology infrastructure, while Africa's adoption is concentrated in select urban centers where neurosurgical capacity, referral networks, and private-sector access are available.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN markets are gaining relevance through medical tourism, private hospital networks, and specialist centers in Singapore, Thailand, and Malaysia, while broader access remains uneven across lower-income member states due to reimbursement gaps and workforce limitations. The GCC is advancing neuromodulation adoption through government-backed healthcare modernization, premium hospital procurement, and rising demand for pain, movement disorder, epilepsy, and rehabilitation services.

The European Union is influential because MDR compliance, health technology assessment processes, and cross-border clinical evidence shape global commercialization standards. BRICS economies offer scale through China, India, Brazil, Russia, and South Africa, but pricing, reimbursement, public procurement, and local manufacturing expectations vary significantly. G7 markets remain the benchmark for clinical evidence, specialist adoption, regulatory discipline, and reimbursement scrutiny, while NATO countries overlap with advanced defense-health priorities involving traumatic injury, chronic pain, rehabilitation, mental health, and neurotechnology research.

Key Country Insights Across Major Neuromodulation Markets

The United States is the global commercial anchor for neuromodulation, supported by FDA pathways, large hospital systems, Medicare coverage dynamics, clinical trial activity, and high chronic pain prevalence. Canada follows a more centralized access model shaped by provincial reimbursement, health technology assessment, and specialist referral pathways. Mexico and Brazil represent the strongest Latin American opportunities due to large patient pools, expanding private healthcare access, and growing neurology and pain-management capacity.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine specialist expertise with reimbursement scrutiny, structured clinical evaluation, and increasing demand from aging populations, while Russia's market is shaped by public procurement and localized access. China is scaling rapidly through hospital investment, domestic medtech capabilities, and neurological care expansion; India combines high unmet need with price sensitivity and uneven specialist access; Japan has deep aging-related demand and advanced clinical infrastructure; South Korea is technology-forward with strong digital health readiness; and Australia benefits from advanced clinical practice, specialist centers, and structured reimbursement pathways.

Actionable Recommendations for Neuromodulation Industry Leaders

Industry leaders should prioritize evidence generation that links neuromodulation to functional improvement, medication reduction, quality-of-life gains, durable symptom control, and lower total cost of care. Market access teams should build payer-ready dossiers using randomized evidence, registries, real-world outcomes, patient-reported measures, and subgroup analyses for chronic pain, Parkinson's disease, epilepsy, depression, overactive bladder, and pelvic health.

Organizations should also invest in AI-enabled programming, cybersecurity-by-design, clinician training, patient education, remote follow-up, and post-market surveillance. Strategic partnerships with hospitals, academic centers, digital health developers, and local distributors will be critical for scaling access in Asia-Pacific, Latin America, the Middle East, and other underpenetrated regions. Leaders should align product design with MRI compatibility, battery longevity, workflow efficiency, and transparent data governance to support adoption by clinicians, payers, and regulators.

Research Methodology

This executive summary is built from a structured secondary-research methodology using publicly available and verifiable sources, including regulatory databases, clinical guidelines, peer-reviewed literature, government health statistics, hospital procurement signals, reimbursement frameworks, and recognized public health organizations such as the WHO, CDC, FDA, NIH, and European regulatory authorities.

Insights were synthesized across disease burden, device innovation, clinical evidence, regulatory pathways, reimbursement maturity, regional healthcare infrastructure, workforce capacity, and adoption indicators. The approach emphasizes data-backed interpretation rather than speculative forecasting, ensuring that strategic conclusions remain credible for executives, investors, manufacturers, healthcare providers, and policy decision-makers.

Conclusion

Neuromodulation is entering a new growth phase defined by precision stimulation, AI-supported personalization, remote care, and stronger outcome accountability. The category is supported by durable clinical need across chronic pain, movement disorders, epilepsy, psychiatric disorders, pelvic health, and autonomic conditions, making it one of the most strategically important segments in neurotechnology.

Future leadership will depend on clinical evidence, reimbursement alignment, responsible AI, device reliability, patient access, and regional execution. Organizations that combine innovation with measurable patient outcomes, secure digital infrastructure, and disciplined market access strategies will be best positioned as neuromodulation becomes more integrated into mainstream neurological, psychiatric, rehabilitation, and pain-management care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Neuromodulation Market, by Product Type

  • 7.1. Deep Brain Stimulation
    • 7.1.1. Directional
    • 7.1.2. Ring
  • 7.2. Sacral Nerve Stimulation
    • 7.2.1. Nonrechargeable
    • 7.2.2. Rechargeable
  • 7.3. Spinal Cord Stimulation
    • 7.3.1. Closed Loop
    • 7.3.2. Open Loop
  • 7.4. Transcutaneous Electrical Nerve Stimulation
    • 7.4.1. Portable
    • 7.4.2. Stationary
  • 7.5. Vagus Nerve Stimulation
    • 7.5.1. Implanted
    • 7.5.2. Noninvasive

8. Neuromodulation Market, by Technology

  • 8.1. Invasive
  • 8.2. Noninvasive

9. Neuromodulation Market, by Patient Age Group

  • 9.1. Pediatric
  • 9.2. Adult
  • 9.3. Geriatric

10. Neuromodulation Market, by Application

  • 10.1. Chronic Pain Management
  • 10.2. Depression
  • 10.3. Epilepsy
  • 10.4. Movement Disorders
  • 10.5. Urinary Incontinence

11. Neuromodulation Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Home Care
  • 11.3. Hospitals

12. Neuromodulation Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Neuromodulation Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Neuromodulation Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. BioControl by Merck
  • 16.3. BioElectronics Corporation
  • 16.4. Boston Scientific Corporation
  • 16.5. EndoStim, Inc.
  • 16.6. Impulse Dynamics
  • 16.7. Livanova
  • 16.8. Mainstay Medical
  • 16.9. Medtronic PLC
  • 16.10. MicroTransponde
  • 16.11. NeuroMetrix
  • 16.12. Neuronetics, Inc.
  • 16.13. NeuroPace, Inc.
  • 16.14. NeuroSigma, Inc.
  • 16.15. Nevro Corp.
  • 16.16. Saluda Medical
  • 16.17. SceneRay Corporation, Limited
  • 16.18. Soterix Medical
  • 16.19. Synapse Biomedical

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROMODULATION MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL NEUROMODULATION MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL NEUROMODULATION MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL NEUROMODULATION MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROMODULATION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL NEUROMODULATION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL NEUROMODULATION MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL NEUROMODULATION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL NEUROMODULATION MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL NEUROMODULATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL NEUROMODULATION MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL NEUROMODULATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DEEP BRAIN STIMULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DEEP BRAIN STIMULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DEEP BRAIN STIMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIRECTIONAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIRECTIONAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DIRECTIONAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SACRAL NERVE STIMULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SACRAL NERVE STIMULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SACRAL NERVE STIMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NONRECHARGEABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NONRECHARGEABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NONRECHARGEABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RECHARGEABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RECHARGEABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RECHARGEABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SPINAL CORD STIMULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SPINAL CORD STIMULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SPINAL CORD STIMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CLOSED LOOP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CLOSED LOOP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CLOSED LOOP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OPEN LOOP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OPEN LOOP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OPEN LOOP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PORTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PORTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PORTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL STATIONARY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL STATIONARY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL STATIONARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VAGUS NERVE STIMULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VAGUS NERVE STIMULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VAGUS NERVE STIMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMPLANTED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMPLANTED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMPLANTED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NONINVASIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NONINVASIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NONINVASIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INVASIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INVASIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INVASIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NONINVASIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NONINVASIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NONINVASIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CHRONIC PAIN MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHRONIC PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CHRONIC PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DEPRESSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DEPRESSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DEPRESSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL EPILEPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL EPILEPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL EPILEPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MOVEMENT DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MOVEMENT DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MOVEMENT DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL URINARY INCONTINENCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL URINARY INCONTINENCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL URINARY INCONTINENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL NEUROMODULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. GCC NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. GCC NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. GCC NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 173. GCC NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 174. GCC NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 175. GCC NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 176. GCC NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 177. GCC NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. GCC NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GCC NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. GCC NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. G7 NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 204. G7 NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. G7 NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 206. G7 NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 207. G7 NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 208. G7 NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 209. G7 NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 210. G7 NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. G7 NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. G7 NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. G7 NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. NATO NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. NATO NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. NATO NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 217. NATO NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 218. NATO NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 219. NATO NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 220. NATO NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 221. NATO NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. NATO NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. NATO NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. NATO NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. CANADA NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 238. CANADA NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. CANADA NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 240. CANADA NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 241. CANADA NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 242. CANADA NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 243. CANADA NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 244. CANADA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. CANADA NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. CANADA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 247. CANADA NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. MEXICO NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 249. MEXICO NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. MEXICO NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 251. MEXICO NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 252. MEXICO NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 253. MEXICO NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 254. MEXICO NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 255. MEXICO NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. MEXICO NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 257. MEXICO NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 258. MEXICO NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. BRAZIL NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. BRAZIL NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. BRAZIL NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 262. BRAZIL NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 263. BRAZIL NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 264. BRAZIL NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 265. BRAZIL NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 266. BRAZIL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 267. BRAZIL NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 268. BRAZIL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. BRAZIL NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED KINGDOM NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. GERMANY NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 282. GERMANY NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. GERMANY NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 284. GERMANY NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 285. GERMANY NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 286. GERMANY NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 287. GERMANY NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 288. GERMANY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 289. GERMANY NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 290. GERMANY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 291. GERMANY NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. FRANCE NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. FRANCE NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. FRANCE NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 295. FRANCE NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 296. FRANCE NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 297. FRANCE NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 298. FRANCE NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 299. FRANCE NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 300. FRANCE NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 301. FRANCE NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 302. FRANCE NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 303. RUSSIA NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 304. RUSSIA NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. RUSSIA NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 306. RUSSIA NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 307. RUSSIA NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 308. RUSSIA NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 309. RUSSIA NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 310. RUSSIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 311. RUSSIA NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 312. RUSSIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 313. RUSSIA NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 314. ITALY NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 315. ITALY NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. ITALY NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 317. ITALY NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 318. ITALY NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 319. ITALY NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 320. ITALY NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 321. ITALY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 322. ITALY NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 323. ITALY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 324. ITALY NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 325. SPAIN NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 326. SPAIN NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. SPAIN NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 328. SPAIN NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 329. SPAIN NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 330. SPAIN NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 331. SPAIN NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 332. SPAIN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 333. SPAIN NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 334. SPAIN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 335. SPAIN NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 336. CHINA NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 337. CHINA NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 338. CHINA NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 339. CHINA NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 340. CHINA NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 341. CHINA NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 342. CHINA NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 343. CHINA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 344. CHINA NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 345. CHINA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 346. CHINA NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 347. INDIA NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 348. INDIA NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 349. INDIA NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 350. INDIA NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 351. INDIA NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 352. INDIA NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 353. INDIA NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 354. INDIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 355. INDIA NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 356. INDIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 357. INDIA NEUROMODULATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 358. JAPAN NEUROMODULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 359. JAPAN NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 360. JAPAN NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 361. JAPAN NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2018-203